
|Videos|October 20, 2017
Dr. Zhang Discusses the Impact of the STAMPEDE Trial in Prostate Cancer
Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.
Advertisement
Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.
The STAMPEDE trial compared abiraterone acetate (Zytiga) to androgen deprivation therapy (ADT) in patients with metastatic and nonmetastatic prostate cancer.
Early disease-free survival benefits are being seen with abiraterone acetate in the nonmetastatic setting, suggesting it could be a marker for overall survival benefit, says Zhang.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
4
TRX103 Tr1 Cell Therapy Shows Manageable Safety and Dose-Dependent Kinetics After HLA-Mismatched HCT in Hematologic Malignancies
5




































